Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

113%

9 of 8 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 3

3(33.3%)

Phase 2

2(22.2%)

9Total

Phase 1(4)

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02806960Phase 1Terminated

A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

Role: collaborator

NCT02171130Phase 3Completed

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Role: collaborator

NCT02806973Phase 1Completed

A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Role: collaborator

NCT01556594Phase 2Completed

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

Role: collaborator

NCT01994746Phase 3Completed

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

Role: collaborator

NCT02778113Phase 1Completed

A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults

Role: collaborator

NCT02778100Phase 1Completed

A Study of Nasal Glucagon in Participants With a Common Cold

Role: collaborator

NCT01959334Phase 3Completed

Evaluate the Immunogenicity of a Novel Glucagon Formulation

Role: collaborator

NCT01997411Phase 2Completed

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Role: collaborator

All 9 trials loaded